Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million in a Series C round from China investors (see story). VectorBuilder develops and optimizes gene delivery products for research institutions and pharma companies. Earlier this year, VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. The C round was co-led by Legend Capital, Suikai Investment (55% owned by state-owned firm Guangzhou Development District Investment Group) and Yuexiu Industrial Fund, a PE investor.